Richard T. Silver
Weill Cornell Medicine · 405 works · 26,910 citations · h-index 66
Top works
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
- Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults
- A Comparative Study of Two Regimens of Combination Chemotherapy in Acute Leukemia
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- Daunorubicin in the therapy of acute granulocytic leukemia.
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- Fever, infection and host resistance in acute leukemia
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- The Role of the Mature Neutrophil in Bacterial Infections in Acute Leukemia
- THE NEUROLOGIC MANIFESTATIONS OF THE ACUTE LEUKEMIAS: A CLINICAL STUDY
- Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
- Characteristics of the Terminal Phase of Chronic Granulocytic Leukemia
- Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
- Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
- JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
- Recombinant Human Erythropoietin Therapy for Anemic Cancer Patients on Combination Chemotherapy